NEOS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.998 SEK | -0.20% |
|
-0.20% | -54.64% |
| 25/04 | NeoDynamics AB Announces CFO Changes | CI |
| 15/04 | Air Astana Partner with Italy-based Neos | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -54.64% | 30.53L | - | ||
| -15.52% | 1.97TCr | A | ||
| -39.00% | 301.11Cr | C+ | ||
| +22.02% | 193.74Cr | - | ||
| -0.62% | 166.1Cr | - | ||
| +35.83% | 133.68Cr | B+ | ||
| -22.01% | 90Cr | - | C- | |
| +6.26% | 83Cr | - | ||
| -23.80% | 64Cr | B+ | ||
| +10.38% | 52Cr | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NEOD Stock
- Ratings NEOS AB